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Themelanocortin2receptor(MC2R)accessoryprotein(MRAP) isasmall single-transmembranedomain
protein thatplays apivotal role in the functionof theMC2R. Thepituitaryhormone,ACTH, acts via this
receptor complex to stimulate adrenal steroidogenesis. Using both coimmunoprecipitation and bi-
oluminescenceresonanceenergy transfer (BRET),weshowthat theMC2R is constitutivelyhomodimer-
ized in cells. Furthermore, consistent with previous data, we also show thatMRAP exists as an antipa-
rallelhomodimer.ACTHenhancedtheBRETsignalbetweenMC2RhomodimersaswellasMC2R-MRAP
heterodimers. However, ACTH did not enhance the physical interaction between these dimers as
determined by coimmunoprecipitation. Real-time BRET analysis of the MRAP-MC2R interaction re-
vealed twodistinct phases of theACTH-dependent BRET increase, an initial complex series of changes
occurringoverthefirst2minandalaterpersistent increase inBRETsignal.TheslowerACTH-dependent
phasewas inhibitedby theprotein kinaseA inhibitor KT5720, suggesting that signal transductionwas
aprerequisite for this laterconformationalchange.TheMRAP-MC2RBRETapproachprovidesaunique
tool with which to analyze the activation of this receptor. (Endocrinology 152: 495–502, 2011)
An intact pituitary-adrenal axis is essential for life.The essential regulatory component of this axis is
the peptide hormone ACTH, which is secreted by the
pituitary corticotroph cells and acts on the adrenal cor-
tex to stimulate steroidogenesis. The receptor mediat-
ing this action is the melanocortin 2 receptor (MC2R),
a member of the melanocortin receptor family that col-
lectively forms a subfamily of the rhodopsin/-adren-
ergic-like family A of the G protein-coupled receptor
(GPCR) superfamily. The MC2R is unique among its
family members in that it is highly selective for the 39-
residue ACTH peptide and does not bind to related -,
-, or -MSH peptides (1). Similar to the other four
members of the melanocortin receptor family, the
MC2R signals primarily via the G protein Gs to stim-
ulate adenylyl cyclase and mediate steroidogenesis by
activating the cAMP/protein kinase A (PKA)-dependent
signaling pathway.
Cell surface expression of a functional MC2R is de-
pendent on the presence of a small single-transmembrane
domain accessory protein known as the MC2R accessory
protein (MRAP) (2). The MC2R is retained at the endo-
plasmic reticulum (ER) when expressed in cells that are
devoid of MRAP. When MC2R is coexpressed with
MRAP, however, as in adrenocortical cell lines or in appro-
priately transfected cells, the MC2R is seen to traffic to the
plasma membrane and to generate a signal in response to
ACTH(2–5).MRAP therefore acts as an accessory factor by
facilitating trafficking of the MC2R to the cell surface.
MRAP appears to have an important additional function in
assisting ACTH binding and consequently signal transduc-
tion(3,4).Mutations inMRAPresult inasyndromeofsevere
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ACTH insensitivity (6, 7), and knockdown of MRAP in an
adrenocortical cell line reduces ACTH responsiveness (8).
MRAP functions as a homodimer that is highly resis-
tant to dissociation by sodium dodecyl sulfate and -mer-
captoethanol as shownby coimmunoprecipitation studies
(8). Furthermore, Sebag and Hinkle (9) have suggested
that this is an antiparallel homodimer, such that one mol-
ecule has its N terminus projecting extracellularly, and its
partner molecule has its N terminus projecting intracel-
lularly, as shown by immunocytochemical and glycosyl-
ation studies. Such a structure is apparently unique in eu-
karyotic biology and raises interesting questions over the
mechanisms of translation and membrane insertion of
these proteins.
Several pieces of data, including fluorescent comple-
mentation studies, indicate that the MRAP homodimer
forms in the ER and that the dimeric form is essential for
the MC2R to be trafficked to the cell surface (10). How-
ever, there is no reported data on the dynamics of the
ACTH receptor complex.We used a bioluminescence res-
onance energy transfer (BRET) approach to study the ho-
mo/heterodimerization of theMC2R andMRAP in living
cells and explore the possibility that receptor activation
may influence the complex. These studies reveal an ap-
parent requirement for a dimeric MC2R that undergoes
conformational change on ACTH stimulation.
Materials and Methods
Reagents
Laboratory reagents and culture media were purchased
from Sigma-Aldrich (Dorset, UK) unless otherwise stated.
ACTH(1–39), ACTH(1–24), and ACTH(1–13) were purchased
from Bachem/Peninsula Laboratories (St Helen’s, Merseyside,
UK), andAngiotensin IIwas purchased fromSigma-Aldrich.The
PKA inhibitor KT5720 and the adenylyl cyclase inhibitor
SQ22536 were purchased fromCalbiochem (Nottingham, UK).
Plasmid constructions and transfections
MRAP-Rluc, Rluc-MRAP, and MC2R-Rluc were generated
by subcloning humanMRAP and humanMC2R into the codon
humanized Renilla luciferase vectors pRLuc N1 and pRLuc C3
(PerkinElmer, Cambridgeshire, UK). Enhanced yellow fluores-
centprotein (EYFP)-MRAPandMC2R-EYFPweregeneratedby
cloning MC2R and MRAP into the expression vectors pEYFP
N1 and C1 (CLONTECH Laboratories, Inc., Mountain view,
CA). AT1R-EYFP was generated by subcloning AT1R into
pEYFP-N1. -Arrestin-Rluc was generated by cloning -arres-
tin2 into pEYFP-N1 and replacing EYFP with Rluc. The un-
tagged humanMRAP construct was obtained by subcloning hu-
man MRAP into pcDNA 3.1() vector (Invitrogen Corp.,
Carlsbad, CA).MRAP 3Flag construct was generated by sub-
cloning humanMRAP into the p3xFlag-CMV-14 vector (Sigma-
Aldrich). The human MC2RxFlag construct was generated by
subcloning human MC2R sequence into the p3xFlag-CMV-14
vector.The receptoractivitymodifyingprotein (RAMP)1-EYFP-
myc construct was a kind gift from Professor Michele Bouvier
(Department of Biochemistry, University of Montreal, Mon-
treal, Quebec, Canada). The BRET-based exchange protein di-
rectly activated by cAMP (EPAC) cAMP biosensor consisting of
the human EPAC1 sequence flanked by citrine (an EYFP) and
Renilla luciferase (11) was kindly provided by Professor Stern-
weis (University of Texas SouthwesternMedical Centre, Dallas,
TX). TheMC2Rx3 hemagglutinin (HA) construct was obtained
fromMissouri University of Science and Technology cDNARe-
source Centre (www.cDNA.org). Human embryonic kidney
(HEK)293A cells were maintained in DMEM containing 10%
fetal calf serum and 1% penicillin/streptomycin. Cells were
transfected with Lipofectamine 2000 (Invitrogen, Paisley, UK).
Coimmunoprecipitations and Western blotting
HEK293 cells were transfected with MRAPx3Flag and/
or MC2Rx3 HA constructs. For the detection of MC2R ho-
modimerization cells were transfectedwithMC2Rx3HA and/or
MC2Rx3Flag constructs. Some cells were stimulated 24 h after
transfection for20minwith106MACTH.Cellswere scraped into
lysis buffer containing PBS  0.1% n-dodecyl- maltoside and a
protease inhibitor cocktail. For coimmunoprecipitations, the ly-
sates were incubatedwith anti-HA agarose beads and incubated at
room temperature for another 2 h. Sodium dodecyl sulfate loading
buffer was added to the samples and subjected toWestern blotting
using a 1:1000 dilution of the antiflag antibody M2. Secondary
antibody IRDye800CWgoat antimouse IgG (LI-CORBiotechnol-
ogy-UK Ltd, Cambridge, UK) was used at a 1:10,000 dilution and
imaged using the LI-COR Odyssey Infrared Image System.
cAMP assay
For cAMP assays HEK293 cells were transfected with
MC2Rx3HA along with either MRAPx3Flag, EYFP-MRAP,
MRAP-Rluc. or Rluc-MRAP DNA constructs. Cells were
stimulated 24 h after transfection with 106 M ACTH for 20
min followed by lysis and assayed using the Tropix cAMP
screen ELISA system (Applied Biosystems, Bedford, MA) ac-
cording to the manufacturer’s instructions.
BRET assays in live cells
For BRET assay HEK293 cells were grown in six-well plates
and transiently transfected as described above. For optimization
of BRET conditions, the donor-acceptor ratio was varied. The
optimum ratio of 1:1 was used for the subsequent transfections.
The expression levels of the donor and acceptor constructs were
observed using fluorescencemicroscopy and luminometry. Cells
were washed 24 h after transfection, detached using PBS, and
then transferred into 96-well black optiplates (PerkinElmer) us-
ing HEPES-buffered Ham’s F-12 media. For endpoint assays,
24 h after transfection, cells were stimulated with ligands for 20
min. Coelenterazine h (Invitrogen) was added in HEPES-buff-
ered Ham’s F-12 to a final concentration of 5 M, and readings
were collected immediately after this additionusing the Polarstar
Omega plate reader (BMG Labtech Ltd, Buckinghamshire, UK)
that allows simultaneous dual emission detection. For real-time
experiments coelenterazine h was added to a final concentration
of 5 M directly before ligand injection.. Readings were taken
immediately at 0.2-sec intervals for 40 sec followed by 3-sec
intervals for 160 sec and 60-sec intervals for 700 sec. Cells were
kept at 37 C throughout the BRET measurements.
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The BRET ratio is defined as emission at 530 nm (light emit-
ted by EYFP)/emission at 485 nm (light emitted by Rluc). The
normalized BRET ratio was calculated by subtracting the BRET
ratio obtained in cells expressing the donor only (Rluc) fromcells
coexpressing both donor (Rluc)- and acceptor (EYFP)-tagged
constructs. To assess the effect of the PKA inhibitor KT5720 or
the adenylyl cyclase inhibitor SQ22536, cells were incubated
with these reagents for 1 h and stimulatedwith ACTH(1–39) for
20 min before the addition of coelenterazine h.
Statistical analysis
The data reported are the mean  SEM of at least three inde-
pendent experiments, each performed at least in duplicate. Sta-
tistical analysis was performed using ANOVA.
Results
MRAP constructs with luciferase engineered onto either
the N or C terminus and MRAP with EYFP at the N ter-
minus were all capable of supporting the functional ex-
pression of theMC2Rwhen transfected individually with
MC2R into HEK293 cells (Fig. 1A), indicating that the
presence of the luminescent or fluorescentmoiety does not
impede the trafficking and signaling role of the MRAP
molecule. Note that these experiments were performed in
the absence of phosphodiesterase inhibitor, as a result of
which cAMP accumulation is modest.
Coexpression of MRAP with N terminally located lu-
ciferase (Rluc-MRAP) and MRAP with N terminally lo-
catedEYFPmoieties (EYFP-MRAP) gave noBRET signal.
In contrast, expression of MRAP with C-terminal lucif-
erase (MRAP-Rluc) in place of the N terminally tagged
variety together with N terminal EYFP-MRAP produced
a significant BRET response (Fig. 1B). These effects were
not enhanced by the presence of ACTH and suggest that
an antiparallel homodimer is the only significant form of
MRAP found in the absence of MC2R. Cotransfection of
MC2R resulted in a small but significant BRET signal in
the case of the parallel homodimeric form of MRAP, but
a sizeable increase in BRET signal in the case of the anti-
parallel form. Stimulation with ACTH did not increase
this signal.The specificityof theMRAPdimer is illustrated
by the finding that no BRET signal is generated between
MRAP and RAMP1 (Fig. 1B).
One explanation for these findings is that the pres-
ence of receptor may influence the relative conforma-
tion or the tightness of the MRAP-MRAP antiparallel
dimer and consequently increase the BRET signal. Al-
ternatively, or perhaps in addition, receptor dimeriza-
tion/oligomerization may bring together additional
MRAP dimers so that BRET between different MRAP
dimers can take place. This would be the case if each
MC2R monomer was accompanied by a single MRAP
homodimer, or even if more than one MRAP ho-
modimer became associated with each MC2R mono-
mer. In support of this latter view is the observation that
parallel homodimer BRET signals become detectable
only in the presence of MC2R.
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FIG. 1. MRAP homodimerization. A, Function of MRAP constructs used
for BRET. HEK293 cells were transfected with MC2Rx3HA along with
either MRAPx3Flag, EYFP-MRAP, MRAP-Rluc, or Rluc-MRAP. Cells were
stimulated 24 h after transfection with 106 M ACTH (without the
addition of isobutylmethylxanthine) and assayed for cAMP (n 3
independent experiments). ***, P 0.001 compared with unstimulated.
B, HEK293 cells were transfected with EYFP-tagged MRAP and MRAP
tagged with Rluc at the C or N termini. Some cells were also transfected
with a MC2Rx3HA construct. Controls included cells transfected with
RAMP1-YFP and Rluc-MRAP, or -arrestin-Rluc and AT1R-YFP
(positive control). Cells were stimulated with ACTH or angiotensin II
(AngII) for 20 min at 106M (n  4 independent experiments).
*, P  0.05; ***, P  0.001.
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A number of studies have suggested that several mela-
nocortin receptors can form homo/heterodimeric struc-
tures (10, 13). We investigated the effect of MRAP and
ACTH on the homodimerization of the MC2R using co-
immunoprecipitation.Coexpression ofMC2Rx3Flag and
MC2Rx3HA followed by Flag immunoprecipitation and
immunoblotting for HA provides evidence forMC2R ho-
modimerization (Fig. 2). The presence of MRAP does not
influence MC2R dimerization, implying that it occurs in
the ER, because the MC2R does not escape the ER in the
absence of MRAP. The reverse coimmunoprecipitations
produced similar results (data not shown). ACTH does
not appear to influence the efficiency of this interaction.
To seek confirmationof this finding,MC2Rwas tagged
with luciferase or EYFP at the C terminus, and a small
BRETsignalwasdetected in the absenceofMRAP.ACTH
was without influence as would be predicted because it is
likely that the MC2R would be located in the ER and
inaccessible to agonist.However,whenMRAPwas cotrans-
fected with MC2R-Rluc and MC2R-EYFP and cells were
stimulatedwithACTH,a significant increase inBRETsignal
was seen. No BRET between MC2R-Rluc and AT1-yellow
fluorescent protein (YFP) was detected, supporting the no-
tion that the MC2R dimer was specific (Fig. 3)
The striking effect of ACTH in this model would most
simply be explained by a conformational change in the
receptor in response to agonist stimulation such that the
twoC-terminal tails of the receptorwere drawn into closer proximity. If this were the case, similar changesmight be
predicted in the interaction between MRAP and the re-
ceptor. Figure 4A demonstrates that this is the case
when N terminally tagged EYFP-MRAP and MC2R-
Rluc show amarked increase in BRET signal in response
to agonist. No BRET signal was seen in cells expressing
MC2R-Rluc and RAMP1-YFP in the absence or pres-
ence of ACTH.
The ACTH(1–39)-induced BRET increase was not ob-
served when the ACTH competitive antagonist, ACTH
(11–24), which binds the receptor but fails to generate a
signal, was used (12). This finding implies that signal gen-
eration is required for this presumed conformational
change. In support of this, stimulation of the receptorwith
ACTH in the presence of the PKA inhibitor KT5720 in-
hibited generation of a BRET signal (Fig. 4A). The use of
the adenylyl cyclase inhibitor SQ 22536 also resulted in a
significant reduction in the ACTH-induced BRET re-
sponse (Fig 4A). An alternative possibility, that agonist
stimulation led to additional recruitment of MRAP into
the receptor complex, was investigated by coimmunopre-
cipitation studies, but no evidence for this occurrence was
found (Fig. 4B). The four bands that are represented by the
arrows in this figure are typical of the appearance of hu-
man MRAP on immunoblotting that we have reported
previously (3). The predicted molecular mass of the hu-
ACTH
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MC2Rx3FLAG
MC2Rx3FLAG
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FIG. 2. MC2R homodimerization demonstrated by
coimmunoprecipitation: MC2Rx3HA, MC2Rx3Flag, and MRAP were
coexpressed in HEK293 cells without and with 20 min of ACTH treatment.
Immunoblot (IB) with anti-Flag (top panel) demonstrates expression of
MC2Rx3Flag (indicated by arrowhead). Anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) immunoblotting (middle panel) shows equal
loading. Coimmunoprecipitation of these samples with anti-HA agarose
beads and immunoblotting with anti-Flag reveals the presence of dimeric
MC2R (lower panel). IP, Immunoprecipitation.
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FIG. 3. MC2R homodimerization demonstrated using BRET. HEK293
cells were transfected with MC2R-Rluc and MC2R-EYFP constructs.
Some cells were also transfected with a MRAPx3Flag construct. As
controls for the assay, cells were transfected with MC2R-Rluc and
AT1R-EYFP or -arrestin-Rluc and AT1R-EYFP (positive control). ACTH
and angiotensin II (ANGII) were used at 106 M concentration for 20
min (n  3 independent experiments). *, P  0.05; ***, P  0.001.
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manMRAPFlag protein is 24 kDa, and
the multiple bands may correspond to
posttranslationally modifiedMRAP or
cleavage products.
All these observations weremade at a
single 20-min time point, but as wewere
interested in the time course of these
changes and their relationship to signal
transduction, the MRAP-MC2R BRET
response was studied in real time. Unex-
pectedly, this revealed the existence of
two distinct phases. Phase 1 begins im-
mediately on addition of ACTH and
consists of a reduction in BRET signal,
followed within a few seconds by a re-
covery of signal strength by 30–60 sec
and a final decline in BRET signal by
about 120 sec.
Phase 2becomes apparent after about
2 min and shows steadily increasing
BRET signal, which persists for up to 25
min (data not shown). cAMP generation
in real time was followed using the
EPAC BRET reporter, which showed
that cAMP began accumulating within
seconds of agonist addition, and this in-
creased steadily thereafter (Fig. 5). In the
presence of KT5720, the first-phase re-
sponse is attenuated and the second
phase is absent, supporting the notion
that PKA signaling is important for both
components. ACTH(1–13), which is un-
able to bind to the MC2R, induced no
BRET response (data not shown).
Discussion
An emerging theme in GPCR biology is
the requirement of some receptors for
accessory proteins that assist trafficking
and ligand binding. The RAMP pro-
teins,which classically associatewith the
calcitonin receptor and calcitonin-like
receptor, provide the prototype for this
class of proteins, and features such as the
associationwith receptor in the ER, traf-
ficking to the plasma membrane, and
contribution to ligand binding and sig-
naling are also identified with the recep-
tor transporting proteins, receptor ex-
pression enhancing protein and MRAP
proteins (2, 16–18).MRAP is unusual in
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FIG. 4. MC2R-MRAP heterodimerization. A, HEK293 cells were transfected with MC2R-RLuc
and EYFP-MRAP. Some cells were incubated with the PKA inhibitor (KT5720; 107 M) or the
adenylyl cyclase inhibitor SQ22536 (106 M)for 1 h before stimulation with 106 M ACTH(1–
39). Some cells were also exposed to ACTH(11–24) antagonist (106 M). As controls for the
assay, cells were transfected with MC2R-RLuc and RAMP1-EYFP or -arrestin-Rluc and AT1R-
EYFP (positive control). Angiotensin II was used at 106 M concentration (n  3 independent
experiments). *, P  0.05; ***, P  0.001. B, Influence of ACTH on the heterodimerization
between MRAP and MC2R using coimmunoprecipitation. HEK293 cells were transfected with
MC2Rx3HA or MRAPx3Flag or coexpressed with both constructs. Cells coexpressing both
proteins were stimulated with media alone or 106 M ACTH for 20 min. Lysates were
immunoprecipitated (IP) with the anti-HA antibody and immunoblotted using anti-Flag
antibody. Human MRAPx3Flag is depicted by the arrowheads.
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that it appears to function as a dimer, and elegant studies
from Sebag andHinkle (9, 10) have made a strong case that
it adopts a unique antiparallel conformation. In the present
work we sought to test this model using BRET. This tech-
nique has the advantage that it enables studies in live cells
and the influence of ligand or othermodulators can be stud-
ied in real time. Our data suggest that the antiparallel con-
formation is the preferred conformation adopted byMRAP.
The magnitude of the BRET signal from this antiparallel
dimer is greatly enhanced in the presence of theMC2R.Two
factorsmay account for this. First, the binding of theMRAP
dimer to the receptor may lead to a conformational change
between the MRAP molecules such that the luciferase and
YFP moieties are brought into closer proximity. Second,
dimerization of receptor molecules, each with an associated
MRAP dimmer, may lead to BRET generation between
MRAP dimers in addition to from within a single MRAP
dimer.
The demonstration that MC2R homodimerizes is
based on coimmunoprecipitation and BRET data. This is
not especially surprising because the majority of GPCRs
studied (including some of the melanocortin receptors)
have demonstrated some evidence of homodimer forma-
tion (13–15, 19). Some authors have suggested that ago-
nist activation of GPCRs induces the formation of dimers
of GPCRs that are otherwise monomeric in their inactive
state. This is largely based on the low BRET or fluores-
cence resonance energy transfer signals observed for these
GPCRs, which are greatly enhanced after exposure to ag-
onist (20–22). The secondmodel, which is consistentwith
the findings reported here for the MC2R, suggests that
GPCRs are constitutively dimerized at the level of the ER
and ligand-induced changes in BRET/fluorescence reso-
nance energy transfer result from con-
formational changes in the preexisting
dimer (23–29).
The interaction ofMRAP andMC2R,
shown previously using coimmunopre-
cipitation in cell lysates, is confirmed us-
ing BRET in living cells. The finding that
ACTH significantly enhanced this signal
was a surprise. The increase in BRET sig-
nal in the presence of ACTH initially
suggested that ACTH may promote the
dimerization between these two pro-
teins. However, the inhibition of this sig-
nal by both a competitive ACTH antag-
onist, a PKA inhibitor, and an adenylyl
cyclase inhibitor suggests that signal gen-
eration is required. Thus it is more likely
that a consequence of PKA activation,
e.g. receptor phosphorylation, induces a
conformational change in the receptor
and/or MRAP that brings the luciferase and YFP molecules
into closer proximity, resulting in a greater BRET signal.
Real-time analysis of theMC2R-MRAP interaction re-
vealed the presence of a complex series of conformational
changes that appear to comprise two distinct phases. The
first phase was a transient short-term response that was
virtually synchronous with cAMP generation. The second
phase was a slower persistent BRET increase that is the
signalmeasured in the initial single timepoint studies (Fig 4),
and this signal was blocked by the PKA antagonist. It is
tempting to speculate that this latter conformational change
correlates with desensitization of the receptor, which we
have previously shown to have a similar time course and to
be PKA dependent (30). Against this, mutagenesis of serine
208 in the MC2R, which was previously found to be a
target of PKA in the mouse MC2R (30), failed to influ-
ence BRET signal generation (data not shown). This
may indicate that the influence of PKA on the human
MC2R is more complex than on the mouse receptor.
The 2 adrenergic receptor is one of the most exten-
sively studied GPCRs and has been used as a model for
understanding agonist binding of GPCRs. Several studies
including fluorescence spectroscopy have shown that 2
adrenoceptor ligandbinding and activation is a kinetically
and conformationally intricate process with evidence
to show the existence of a sequence of conformational
changes linking the inactive receptor to a fully active re-
ceptor (31, 32). Studies have suggested that the slow and
rapid conformational states generated during agonist
binding may have unique functional properties including
activation of signaling cascades via cAMP production as
well as promoting internalization of the receptor.
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FIG. 5. Real-time BRET analysis on the MRAP-MC2R interaction. HEK293 cells were
transfected with EYFP-MRAP and MC2R-RLuc. A, Cells were stimulated with ACTH(1–39) in
the absence (blue solid diamond), and in the presence of the PKA inhibitor KT5720 (magenta
solid diamond). The production of cAMP in real time was monitored by transfecting cells with
MC2Rx3HA, MRAPx3 Flag, and EPAC constructs (red solid square). Cells expressing EPAC
alone were used to monitor background levels of cAMP (green solid triangle). B, The same
data as in panel A shown on an expanded scale over the first 100 sec.
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Further investigations of other GPCRs, including time-
resolved peptide binding studies of the neurokinin recep-
tor showed that neurokinin binds and activates its recep-
tor in a biphasicmanner. The rapid binding component of
neurokinin A to tachykinin receptors was associated with
a cellular calcium response. The rate of calcium elevation
was found to correlate with the extent of receptor occu-
pancy. The slow component was required for cAMP ac-
cumulation and signaling (33) and was detected after 1.5
min and reached a plateau at about 15–30min. In the case
of the -2 adrenergic receptor, the rapid conformational
change was suggested to be sufficient for activating Gs,
whereas the slow conformational changewas required for
efficient agonist-induced internalization (32).
The combinationof coimmunoprecipitation andBRET
studies reported here, together with information already
published on the MRAP/MC2R interaction, enable us to
construct a model for formation and trafficking of this
complex. The key elements of this model are:-
1. MRAP forms an antiparallel homodimer in the ER.
2. MC2R forms a homodimer in the ER.
3. Either concomitantly or sequentially a complex con-
sisting (at a minimum) of one MC2R homodimer
and two antiparallel MRAP homodimers forms in
theERandmay then traffic to theplasmamembrane.
4. At the cell surface, one or possibly two molecules of
ACTH bind to the hexameric receptor complex. Li-
gandbinding induces a rapid conformational change
and subsequent relaxation of the complex.
5. PKA activation by cAMP leads directly or indirectly
to a modification of the receptor complex, possibly
by a phosphorylation step, whichmay initiate recep-
tor desensitization.
This model provides several testable steps and may
identify actions that may be susceptible to pharmacolog-
ical intervention with potential therapeutic benefit. Argu-
ably, the existence of MRAP as an accessory protein for
this receptor provides a unique tool for study of GPCR
activation,whichmayhave implications beyond themela-
nocortin subfamily of receptors.
Acknowledgments
Address all correspondence and requests for reprints to: Pro-
fessor Adrian J. L.Clark, Barts and the London School of
Medicine & Dentistry, Queen Mary University of London,
Charterhouse Square, London EC1M 6BQ, United Kingdom.
E-mail: a.j.clark@qmul.ac.uk.
This work was supported by Medical Research Council
(G0601140).
Disclosure Summary: The authors of this manuscript have
nothing to declare.
References
1. Schio¨th HB, Chhajlani V, Muceniece R, Klusa V, Wikberg JE 1996
Major pharmacological distinction of the ACTH receptor from
other melanocortin receptors. Life Sci 59:797–801
2. Metherell LA, Chapple JP, Cooray S, David A, Becker C, Ruschen-
dorf F, Naville D, Begeot M, Khoo B, Nurnberg P, Huebner A,
Cheetham ME, Clark A 2005Mutations inMRAP, encoding a new
interacting partner of the ACTH receptor, cause familial glucocor-
ticoid deficiency type 2. J Nat Genet 37:166–170
3. Webb TR, Chan L, Cooray SN, Cheetham ME, Chapple JP, Clark
AJ2009Distinctmelanocortin2 receptor accessoryproteindomains
are required for melanocortin 2 receptor interaction and promotion
of receptor trafficking. Endocrinology 150:720–726
4. Sebag JA, Hinkle PM 2009 Regions of melanocortin 2 (MC2) re-
ceptor accessory protein necessary for dual topology and MC2 re-
ceptor trafficking and signaling. J Biol Chem 284:610–618
5. Roy S, Rached M, Gallo-Payet N 2007Differential regulation of the
human adrenocorticotropin receptor [melanocortin-2 receptor
(MC2R)] by human MC2R accessory protein isoforms  and  in
isogenic human embryonic kidney 293 cells. Mol Endocrinol 21:
1656–1669
6. Metherell LA, Chan LF, Clark AJ 2006 The genetics of ACTH re-
sistance syndromes. Best Pract Res Clin Endocrinol Metab 20:547–
560
7. Chung TT, Chan LF, Metherell LA, Clark AJ2009Phenotypic char-
acteristics of familial glucocorticoid deficiency (FGD) type 1 and 2.
Clin Endocrinol (Oxf) 72:589–594
8. Cooray SN, Almiro Do Vale I, Leung KY, Webb TR, Chapple JP,
Egertova´ M, Cheetham ME, Elphick MR, Clark AJ 2008 The mela-
nocortin 2 receptor accessory protein exists as a homodimer and is
essential for the functionof themelanocortin 2 receptor in themouse
y1 cell line. Endocrinology 149:1935–1941
9. Sebag JA, Hinkle PM 2007Melanocortin-2 receptor accessory pro-
teinMRAP forms antiparallel homodimers. ProcNatl Acad Sci USA
104:20244–20249
10. Sebag JA, Hinkle PM 2009 Opposite effects of the melanocortin-2
((MC2) receptor accessory protein MRAP on MC2 and MC5 re-
ceptor dimerization and trafficking. J Biol Chem284:22641–22648
11. Jiang LI, Collins J, Davis R, Lin KM, DeCamp D, Roach T, Hsueh
R, Rebres RA, Ross EM, Taussig R, Fraser I, Sternweis PC 2007Use
of a cAMP BRET sensor to characterize a novel regulation of cAMP
by the sphingosine 1-phosphatase/G13 pathway. J Biol Chem 282:
10576–10584
12. Seelig S, Sayers G, Schwyzer R, Schiller P1971 Isolated adrenal cells:
ACTH (11–24), a competitive antagonist of ACTH(1–39) and
ACTH(1–10). FEBS Lett 19:232–234
13. Mandrika I, Petrovska R, Wikberg J 2005 Melanocortin receptors
form constitutive homo- and heterodimers. Biochem Biophys Res
Commun 326:349–354
14. Nickolls SA, Maki RA 2006 Dimerization of the melanocortin 4
receptor: a study using bioluminescence resonance energy transfer.
Peptides 27:380–387
15. Zanna PT, Sa´nchez-Laorden BL, Pe´rez-Oliva AB, Turpin MC, Her-
raiz, C, Jime´nez-Cervantes C, Garcı´a-Borro´n JC 2008 Mechanism
of dimerization of the human melanocortin 1 receptor. Biochem
Biophys Res Commun 368:211–216
16. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson
N, Solari R, Lee MG, Foord SM1998RAMPs regulate the transport
and ligand specificity of the calcitonin-receptor-like receptor. Na-
ture 393:333–339
17. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Labur-
the M, Couvineau A, Kuwasako K, Tilakaratne N, Sexton PM 2003
Novel receptor partners and function of receptor activity-modifying
proteins. J Biol Chem 278:3293–3297
18. Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H 2004 RTP
family members induce functional expression of mammalian odor-
ant receptors. Cell 119:679–691
Endocrinology, February 2011, 152(2):495–502 endo.endojournals.org 501
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 August 2014. at 03:50 For personal use only. No other uses without permission. . All rights reserved.
19. Szidonya L, Cserzo M, Hunyady LJ 2008 Dimerization and oli-
gomerization of G-protein-coupled receptors; debated structures
with established and emerging functions. J Endocrinol 196:435–
453
20. Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LE, Eidne KA2001
Constitutive and agonist-dependent homo-oligomerization of the
thyrotropin-releasing hormone receptor. Detection in living cells
using bioluminescence resonance energy transfer. J Biol Chem 276:
12736–12743
21. Wurch T, Matsumoto A, Pauwels PJ2001Agonist-independent and
-dependent oligomerizationof dopamineD(2) receptors by fusion to
fluorescent proteins. FEBS Lett 507:109–113
22. Cornea A, Janovick JA, Maya-Nu´n˜ez G, Conn PM 2001 Gonado-
tropin-releasing hormone receptor microaggregation. Rate moni-
tored by fluorescence resonance energy transfer. J Biol Chem 276:
2153–2158
23. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M,
Bouvier M 2000 Detection of 2-adrenergic receptor dimerization
in living cells using bioluminescence resonance energy transfer
(BRET). Proc Natl Acad Sci USA 97:3684–3689
24. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P,
Bouvier M, Jockers RJ 2002 Monitoring of ligand-independent
dimerization and ligand-induced conformational changes of mela-
tonin receptors in living cells by bioluminescence resonance energy
transfer. J Biol Chem 277:21522–21528
25. Ayoub MA, Levoye A, Delagrange P, Jockers R 2004 Preferential
formation of MT1/MT2 melanocortin receptor heterodimers with
distinct ligand interaction properties compared with MT2 ho-
modimers. Mol Pharmacol 66:312–321
26. Tateyama M, Abe H, Nakata H, Saito O, Kubo Y 2004 Ligand-
induced rearrangement of the dimeric metabotropic glutamate re-
ceptor 2. Nat Struct Mol Biol 11:637–642
27. Couturier C, Jockers R 2003 Activation of the leptin receptor by a
ligand induced conformational change of constitutive receptor dim-
mers. J Biol Chem 278:26604–26611
28. Mercier JF, Salahpour A, Angers S, Breit A, Bouvier MJ2002Quan-
titative assessment of 1 and 2-adrenergic receptor homo- and
heterodimerization by bioluminescence resonance energy transfer.
J Biol Chem 277:44925–44931
29. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tama-
mura H, Fujii N, Bouvier M, Heveker N 2005 Bioluminescence
resonance energy transfer reveals ligand-induced conformational
changes in CXCR4 homo- and heterodimers. J Biol Chem
280:9895–9903
30. Baig AH, Swords FM, Noon LA, King PJ, Hunyady L, Clark AJ
2001 Desensitization of the Y1 adrenocorticotropin receptor: evi-
dence for a restricted heterologous mechanism implying a role for
receptor-effector complexes. J Biol Chem 276:44792–44797
31. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK 2001 Agonist-
induced conformational changes in the G-protein-coupling domain
of the 2 adrenergic receptor. Proc Natl Acad Sci USA 98:5997–
6002
32. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK
2004 Sequential binding of agonists to the 2 adrenoceptor. Kinetic
evidence for intermediate conformational states. J Biol Chem 279:
686–691
33. Palanche T, Ilien B, Zoffmann S, Reck MP, Bucher B, Edelstein SJ,
Galzi JL 2001 The neurokinin A receptor activates calcium and
cAMP responses through distinct conformational states. J Biol
Chem 276:34853–34861
Earn CME Credit for  
“Approach to the Patient” articles in JCEM!
www.endo-society.org
502 Cooray et al. MRAP-MC2R BRET Studies Endocrinology, February 2011, 152(2):495–502
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 August 2014. at 03:50 For personal use only. No other uses without permission. . All rights reserved.
